Burkitt LymphomaSymptoms, Doctors, Treatments, Advances & More
Learn About Burkitt Lymphoma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Emory Winship Cancer Institute
Kristie Blum is a Hematologist Oncology provider practicing medicine in Atlanta, Georgia. She has been practicing medicine for over 29 years. Dr. Blum is rated as an Elite provider by MediFind in the treatment of Burkitt Lymphoma. She is also highly rated in 20 other conditions, according to our data. Her clinical expertise encompasses Mantle Cell Lymphoma (MCL), Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Blum is board certified in American Board Of Internal Medicine, 2004.
Cardiology Consultants
Mitchell Cairo is a Pediatrics provider practicing medicine in Hawthorne, New York. Dr. Cairo is rated as an Elite provider by MediFind in the treatment of Burkitt Lymphoma. He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Burkitt Lymphoma, Primary Mediastinal B-Cell Lymphoma (PMBCL), B-Cell Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Transplant.
Jackson Orem practices practicing medicine in Kampala, Uganda. Mr. Orem is rated as an Elite expert by MediFind in the treatment of Burkitt Lymphoma. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Burkitt Lymphoma, Kaposi Sarcoma, B-Cell Lymphoma, Tissue Biopsy, and Gastrostomy.
Summary: Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT). If patients achieve either complete, partial, or stable response following ASCT, they will receive an IV dose of Polatuzumab Vedotin once every 21 days until they receive 8 doses. After Polatuzumab Vedotin therapy is completed, patients will be followed every 4 months fo...
Summary: Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.